NYSE:MCCapital Markets
AstraZeneca Merger Talks Shine A Light On Healthcare Deal Advisors
The potential US$400b merger talks between AstraZeneca and Bristol Myers Squibb have thrown a fresh spotlight on the ecosystem that sits behind every big pharma deal. Advisory, legal, and M&A service providers that focus on healthcare can feel the ripple effects of this kind of headline, even while AstraZeneca shares themselves react sharply, with a drop of over 7% on the news. This article looks at how this development might influence deal related activity and what that could mean for...